A comprehensively characterized large panel of head and neck cancer patient-derived xenografts identifies the mTOR inhibitor everolimus as potential new treatment option-Reference-Cited by-同舟云学术

A comprehensively characterized large panel of head and neck cancer patient-derived xenografts identifies the mTOR inhibitor everolimus as potential new treatment option

Published:2014-11-26 Issue:12 Volume:136 Page:2940-2948
ISSN:0020-7136
Container-title:International Journal of Cancer
language:en
Short-container-title:Int. J. Cancer

Author:

Klinghammer Konrad¹²,Raguse Jan-Dirk³,Plath Thomas³,Albers Andreas E.⁴,Joehrens Korinna⁵,Zakarneh Andre⁶,Brzezicha Bernadette⁷,Wulf-Goldenberg Annika⁷,Keilholz Ulrich⁸,Hoffmann Jens⁷,Fichtner Iduna²⁷

Affiliation:

1. Department of Hematology and Oncology; Charité University Medicine; Berlin Germany

2. Department of Experimental Pharmacology; Max Delbrueck Center; Berlin Germany

3. Department of Maxillio-Facial Surgery; Charité University Medicine; Berlin Germany

4. Department of ENT; Charité University Medicine; Berlin Germany

5. Department of Pathology; Charité University Medicine; Berlin Germany

6. Department of ENT; St. Gertrauden Hospital Berlin; Berlin Germany

7. EPO-Experimental Pharmacology and Oncology GmbH; Berlin Germany

8. Charité Cancer Comprehensive Center; Berlin Germany

Funder

Sander Stiftung

Publisher